{"entity":{"id":"nct06799637","kind":"trial","name":"Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments","aka":[],"tldr":"A phase 1/2 trial of XNW28012 in pancreatic ductal adenocarcinoma, ovarian cancer and cervical cancer, run by Evopoint Biosciences Inc., now recruiting.","summary":"Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments is a phase 1/2 interventional study registered as NCT06799637 by Evopoint Biosciences Inc., with 350 participants planned, started 2023-12-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: XNW28012.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06799637","url":"https://clinicaltrials.gov/study/NCT06799637"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","ovarian","cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["evopoint-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06799637","phase":"1/2","setting":"A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Efficacy of XNW28012 in Subjects With Advanced Solid Tumors","sponsor":"Evopoint Biosciences Inc.","enrolled":350,"outcomes":[]},"route":"/trials/nct06799637/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"evopoint-biosciences","kind":"company","name":"Evopoint Biosciences","route":"/companies/evopoint-biosciences/"}]}}